Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
about
Increased Alpha Band Functional Connectivity Following the Quadrato Motor Training: A Longitudinal Study.An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patientsApplied neurogenomics.Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohortDonepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsCorrelates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.Pharmacogenomics and therapeutic prospects in Alzheimer's disease.Network dysfunction in α-synuclein transgenic mice and human Lewy body dementia.Pharmaco-EEG in psychiatry.Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease.Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease.Electroencephalographic rhythms in Alzheimer's disease.Pharmacogenomics in neurology: current state and future steps.Cognitive predictors of donepezil therapy response in Alzheimer disease.Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.Pharmacogenomics and personalised medicine. SMI Conference on Pharmacogenomics and Personalised Medicine, 26-28 September, 2001, The Hatton, London, UK.Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.QEEG monitoring of Alzheimer's disease treatment: a preliminary report of three case studies.Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer's disease.
P2860
Q33785639-9B7E37C2-1EC7-40DB-8790-ACCF8CB387CFQ34038332-661FDAC6-42CE-4FB8-90D9-5F9E20C30703Q34258228-7435C5FE-4E58-4F52-8169-BFB22EE060CAQ34466802-488BB5D4-94E0-4E32-B895-E73D8AD9CA2DQ34965949-78D13852-7E2C-402A-8645-69C3408A3738Q35066849-4234FEA9-13E4-4149-A6BA-6557F265FCA7Q35486605-59FD3B42-A703-4DD7-A734-B97A203A8FA0Q35852564-082E064D-72F7-479B-BFF6-B71F2F4B2AA9Q36273420-F488A785-9D28-4DDF-8056-AE51E5C5D6DDQ36410380-8D4BDB2E-F852-483B-9909-B72A84529B3AQ36492216-52C38005-EF1F-41C2-A93B-77F82A8A42B3Q36846711-6E779CC3-F9F3-4EF4-B1AA-67A6A5C85F8AQ37031522-07B17BB1-16BD-456E-A348-A3B799348D07Q37044205-85580EB7-CF08-408D-9CE7-15FE7A08C2D5Q37092283-9837181E-FBDE-4790-A21F-5E3240BB95D1Q37690649-6880699A-1823-4437-A7ED-0B42F53A154CQ37691138-D65ED4B4-5570-4EE1-B692-ED8DB92FA854Q37883098-CAA416D5-4A22-4B76-8EF8-AC0EC4C78F58Q37967607-55A26883-505E-4E8E-9CAC-094E96590265Q38397411-85638FAE-DE03-48E9-81B8-E3146F469FBEQ42644052-17AB2162-CCCB-4751-BD23-2527CC4471BFQ44163441-04D9F4A1-794A-435B-BC61-7882F57AAD64Q44828253-15E33DF7-5033-44DE-83D4-2D6311E5F653Q46453360-EBD95F36-009C-462B-A9A4-06F795A4BA80Q46653039-8EE3B7C4-99C0-45EC-9748-9D0C42311313Q51847733-83126397-163D-4A2D-83C0-E0814963E33FQ54979695-1EDDAB54-A1CE-491C-AEF3-EF7C750040D5
P2860
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Responder characteristics to a ...... tacrine in Alzheimer patients.
@en
Responder characteristics to a ...... tacrine in Alzheimer patients.
@nl
type
label
Responder characteristics to a ...... tacrine in Alzheimer patients.
@en
Responder characteristics to a ...... tacrine in Alzheimer patients.
@nl
prefLabel
Responder characteristics to a ...... tacrine in Alzheimer patients.
@en
Responder characteristics to a ...... tacrine in Alzheimer patients.
@nl
P2093
P356
P1476
Responder characteristics to a ...... tacrine in Alzheimer patients.
@en
P2093
E Hellström-Lindahl
L Meurling
P356
10.1159/000051232
P577
2001-01-01T00:00:00Z